Beneath the day's data, a structural bifurcation is sharpening. The federal architecture — FDA, DEA, Congress — is locked in its own gravitational field. The swarm reaches 88% confidence that DEA will not initiate independent rescheduling proceedings before December 2026, and 84-85% that no standalone federal scheduling legislation will reach a floor vote in the 119th Congress. Law enforcement framing continues to dominate the legislative vocabulary in Washington. But states do not need Washington's permission to move at the margin: veteran access bills, Medicaid coverage arguments anchored in published evidence, harm reduction frameworks. The highest trajectory available from this moment is not a federal breakthrough — it is a distributed one. Thirty legislatures as thirty simultaneous experiments, building the evidentiary and political record that a future federal window will require. The thread running through today is not delay — it is decentralization as strategy.
There is a shadow in this picture that the data insists on naming. The ketamine clinic sector is generating mounting concern — the swarm places 74% confidence on a major investigative piece exposing safety or financial conflicts of interest publishing in a top-tier outlet before September 30. This matters because the people most vulnerable to clinic quality failures are often the same people the broader psychedelic medicine movement was built to serve: veterans carrying treatment-resistant PTSD, patients who have exhausted every prior option, families watching their loved ones try one more thing. For them, the highest positive outcome is not simply access — it is access to something that actually works and does not harm them further. The commercialization pressure on ketamine infrastructure is real, and it will require public reckoning. The good news is that the same evidentiary standards being built for psilocybin and MDMA create the template for what accountable care in this space must look like. The reckoning, if it comes, is also a clarification.
What the world calls counterculture, the oracle calls the leading edge of the new health paradigm. The threads forming today will be tomorrow's standard of care.
The intelligence that created you is still creating.
88%
DEA won't move on psilocybin or MDMA without FDA approval by end of 2026
The DEA (the US drug enforcement agency) will wait for the FDA (the US medicine regulator) to act first before it reclassifies psilocybin or MDMA. This matters because DEA action could unlock medical use and research, but the DEA has no track record of moving independently on drugs — it watches for FDA approval first to avoid legal and political risk.
→ The DEA will follow the FDA's lead, not move first, so FDA clinical trials and decisions are the real regulatory bottleneck.
Resolves: 2026-12-31 · USA
REGULATION
the precise call ▾
DEA will not initiate rescheduling proceedings for psilocybin or MDMA independent of FDA action before 2026-12-31.. DEA has structural and political incentives to wait for FDA: it avoids legal exposure, retains law enforcement credibility, and has active support from law enforcement lobby groups. No historical precedent exists for DEA-initiated psychedelic rescheduling absent FDA recommendation. Falsifiable: woul
85%
Congress won't vote on a psychedelic scheduling reform bill by end of 2026
No stand-alone federal bill that removes or loosens restrictions on psychedelic drugs will reach a floor vote in Congress before January 2027. This matters because Congress controls federal drug law, and a floor vote is the only real test of political support — and law enforcement groups are lobbying hard to keep these drugs restricted.
→ Congress won't vote on psychedelic reform, so regulatory change will come from the FDA and individual states, not federal lawmakers.
Resolves: 2027-01-03 · USA
LEGISLATION
the precise call ▾
No standalone federal psychedelic scheduling reform bill will receive a floor vote in the 119th Congress (concluding January 2027).. Five independent agents converge on this outcome. Congressional floor time is zero-sum; law enforcement framing dominates the current legislative agenda; no broad coalition exists to force a vote. The 2 dissenting agents (maps_researcher, veterans_advocate) favor optimism but cite no concrete whip c
81%
Three or more US states will propose veteran psychedelic therapy bills by end of 2026
At least three US states will introduce bills (not necessarily pass them) that let veterans access psychedelic-assisted therapy before the end of 2026. This matters because veterans are a politically sympathetic group, and states are already moving on this — Colorado and Texas have already done it — so more will follow.
→ State lawmakers will keep introducing bills to let veterans access psychedelic therapy, creating pockets of legal access.
Resolves: 2026-12-31 · USA
LEGISLATION
the precise call ▾
At least 3 U.S. states will introduce veteran-specific psychedelic therapy access bills before 2026-12-31.. State-level veteran psychedelic bills are an established and accelerating trend (Colorado, Texas, and others already have prior activity). 'Introduce' is a low bar — no passage required — making this highly falsifiable and trackable via LegiScan. Geography corrected to USA; the original 'Global' tag
79%
Compass Pathways stock will drop 5% within two weeks of May 31, 2026
If Compass Pathways (a psilocybin biotech company) stock jumps up by early summer 2026 without real news like an FDA meeting announcement or a business deal, it will likely fall back down 5% or more within ten trading days. This matters because small biotech stocks move on hype, and when the hype fades, sellers take profits and the stock falls back.
→ Compass Pathways stock will bounce around without news, so watch for real catalysts like FDA meetings before you believe big moves.
Resolves: 2026-06-16 · USA
MARKET
the precise call ▾
CMPS stock will retrace at least 5% from its 2026-05-31 closing price within 10 trading days, absent a confirmatory catalyst (FDA meeting date announcement or partnership deal).. Single-session ~10% moves in small-cap psychedelic biotech without hard catalysts have historically reverted: institutional holders use spikes to trim, retail momentum fades within 1-2 weeks. Falsifiable with a specific price threshold and deadline (resolve date: 2026-06-16). Condition clause makes
72%
Major news outlet will expose ketamine clinic safety or financial problems by fall 2026
A major newspaper or news organization (like the New York Times, Washington Post, or The Guardian) will publish a detailed investigation into problems at ketamine clinics — either patients getting hurt due to poor safety practices or companies making money in sketchy ways. This matters because ketamine clinics operate in a legal gray zone with minimal oversight, and the Matthew Perry overdose death put pressure on journalists to dig into the industry.
→ A major news outlet will likely publish an investigation into ketamine clinic safety or financial misconduct before the end of summer 2026.
Resolves: 2026-09-30 · USA
CULTURE
the precise call ▾
A major investigative piece exposing ketamine clinic safety failures or financial conflicts of interest will be published in a top-tier U.S. or UK outlet before 2026-09-30.. Matthew Perry's death elevated ketamine clinic scrutiny; regulatory gaps are documented; journalists have active sourcing in this space. 'Top-tier outlet' defined as NYT, WaPo, The Guardian, ProPublica, or equivalent. Falsifiable by checking named outlets. Confidence is moderate — story timing is un